BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34730199)

  • 21. RNF185 antisense RNA 1 (RNF185-AS1) promotes proliferation, migration, and invasion in papillary thyroid carcinoma.
    Liu D; Zhang M; Song Y; Yang N
    Anticancer Drugs; 2022 Jul; 33(6):595-606. PubMed ID: 35324519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p.
    Chen T; Qin S; Gu Y; Pan H; Bian D
    Mol Genet Genomic Med; 2019 Aug; 7(8):e757. PubMed ID: 31207175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-3653-3p inhibited papillary thyroid carcinoma progression by regulating CRIPTO-1.
    Bai X; Xu Y; Liu Y
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):272-276. PubMed ID: 38279419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p.
    Xu C; Zhu LX; Sun DM; Yao H; Han DX
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1672-1681. PubMed ID: 32141533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
    Zheng H; Fu Q; Ma K; Shi S; Fu Y
    Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
    Xue KC; Hu DD; Zhao L; Li N; Shen HY
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. lncRNA RPL34-AS1 inhibits cell proliferation and invasion while promoting apoptosis by competitively binding miR-3663-3p/RGS4 in papillary thyroid cancer.
    Ji L; Fan X; Zhou F; Gu J; Deng X
    J Cell Physiol; 2020 Apr; 235(4):3669-3678. PubMed ID: 31587286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circular RNA Pvt1 oncogene (CircPVT1) promotes the progression of papillary thyroid carcinoma by activating the Wnt/β-catenin signaling pathway and modulating the ratio of microRNA-195 (miR-195) to vascular endothelial growth factor A (VEGFA) expression.
    Zeng L; Yuan S; Zhou P; Gong J; Kong X; Wu M
    Bioengineered; 2021 Dec; 12(2):11795-11810. PubMed ID: 34927541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
    Chen Y; Li Y; Gao H
    Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
    Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
    Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HOTAIRM1/miR-107/TDG axis regulates papillary thyroid cancer cell proliferation and invasion.
    Li D; Chai L; Yu X; Song Y; Zhu X; Fan S; Jiang W; Qiao T; Tong J; Liu S; Fan L; Lv Z
    Cell Death Dis; 2020 Apr; 11(4):227. PubMed ID: 32269214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
    Pang R; Yang S
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of long non-coding RNA NORAD promotes invasion and migration in malignant melanoma via regulating the MIR-205-EGLN2 pathway.
    Chen Y; Cao K; Li J; Wang A; Sun L; Tang J; Xiong W; Zhou X; Chen X; Zhou J; Liu Y
    Cancer Med; 2019 Apr; 8(4):1744-1754. PubMed ID: 30843652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long noncoding RNA small nucleolar RNA host gene 12 promotes papillary thyroid carcinoma cell growth and invasion by targeting miR-16-5p.
    Feng X; Dong X; Wu D; Zhao H; Xu C; Li H
    Histol Histopathol; 2020 Feb; 35(2):217-224. PubMed ID: 31355416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
    Gao H; Sun X; Wang H; Zheng Y
    Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Knockdown of circPUM1 impedes cell growth, metastasis and glycolysis of papillary thyroid cancer via enhancing MAPK1 expression by serving as the sponge of miR-21-5p.
    Li Y; Qin J; He Z; Cui G; Zhang K; Wu B
    Genes Genomics; 2021 Feb; 43(2):141-150. PubMed ID: 33481227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a.
    Yan DG; Liu N; Chao M; Tu YY; Liu WS
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1134-1144. PubMed ID: 30779082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
    Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
    Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long non-coding RNA AGAP2-AS1 promotes proliferation and metastasis in papillary thyroid cancer by miR-628-5p/KLF12 axis.
    Xu C; Shao Y; Liu J; Yao X; Quan F; Zhao Q; Zhao R; Kou B; Li H; Han P; Wang X; Bai Y; Zheng Z; Zhang S
    J Bioenerg Biomembr; 2021 Apr; 53(2):235-245. PubMed ID: 33604734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis.
    Li G; Kong Q
    Biol Res; 2019 Dec; 52(1):61. PubMed ID: 31870440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.